Recent investigations have centered on the convergence of glucagon-like peptide-1|GIP|GCGR activator therapies and dopamine signaling. While GLP stimulators are increasingly employed for managing type 2 T2DM, their emerging consequences on reward circuits, specifically governed by DA systems, are